Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru
- Jose G Somocurcio1,
- Alfredo Sotomayor1,
- Sonya Shin2,
- Silvia Portilla1,
- Maria Valcarcel1,
- Dalia Guerra3,
- Jennifer Furin2
- 1Ministerio de Salud, Lima, Perú
- 2Division of Social Medicine and Health Inequalities, Brigham and Women’s Hospital, Boston, Massachusetts, USA
- 3Socios en Salud, Lima, Peru
- Correspondence to:
Dr Jennifer Furin
Brigham and Women’s Hospital, Division of Social Medicine and Health Inequalities, 1620 Tremont Street, Third Floor, Boston, Massachusetts 02120, USA; jfurin{at}partners.org
- Received 25 August 2005
- Accepted 15 June 2006
- Published Online First 23 August 2006
Abstract
Background: While most patients with tuberculosis (TB) can be successfully treated using short-course medical chemotherapy, thoracic surgery is an important adjunctive strategy for many patients with drug-resistant disease. The need for physical, technical and financial resources presents a potential challenge to implementing surgery as a component of treatment for multidrug-resistant TB (MDR-TB) in resource-poor settings. However, a cohort of patients with severe MDR-TB in Lima, Peru underwent surgery as part of their treatment.
Methods: 121 patients underwent pulmonary surgery for drug-resistant tuberculosis between May 1999 and January 2004. Surgery was performed by a team of thoracic surgeons under the Ministry of Health. Patient demographic data, clinical characteristics, surgical procedures and surgical outcomes were studied.
Results: Most of the patients had failed multiple TB regimens and were resistant to a median of seven drugs. The median time of follow-up after surgery was 33 months. 79.3% of patients were culture-positive before surgery, and sustained culture-negative status among survivors was achieved in 74.8% of patients. 63% of those followed up for at least 6 months after surgery were either cured or probably cured. Postoperative complications, observed in 22.6% of patients, were associated with preoperative haemoptysis, vital capacity <50% and low forced expiratory volume in 1 s.
Conclusions: This is one of the largest cohorts with MDR-TB to be treated with surgery, and the first from a resource-poor country. Although surgery is not often considered an option for patients in resource-poor settings, the findings of this study support the argument that adjunctive surgery should be considered an integral component of MDR-TB treatment programmes, even in poor countries such as Peru.
Footnotes
-
Published Online First 23 August 2006
-
This study was funded by grants from the Bill and Melinda Gates Foundation and the Thomas J White Foundation.
-
Competing interests: None.








